Gabapentin dependence is a medical condition that requires supervised care to treat safely.
Gabapentin (Neurontin) is a prescription anticonvulsant that causes genuine physical dependence and carries a high-risk withdrawal profile. At Jintara, we provide psychiatrist-led medical detox for gabapentin addiction, including polysubstance cases involving opioids, as part of our prescription drug addiction treatment in Chiang Mai.
- Psychiatrist assessment on arrival, with a detox taper calibrated to each client's clinical history
- 24/7 awake nursing with vital signs monitored throughout the acute phase
- Day 2 full diagnostic workup at Bangkok Hospital Chiang Mai or RAM Hospital
- Dual diagnosis support for the anxiety, pain, or opioid dependence driving gabapentin use
Fully Licensed Facility
Gabapentin creates genuine physical dependence even when taken as prescribed.
Gabapentin dependence is a physiological state in which the body adapts to the continued presence of the drug and produces withdrawal symptoms when the dose is reduced or stopped. Originally developed as an anticonvulsant and approved for nerve pain, gabapentin acts on voltage-gated calcium channels in the brain, dampening neuronal excitability in a manner similar to other central nervous system depressants. That mechanism is also what makes dependence possible: the brain adjusts its baseline activity to compensate, and when gabapentin is removed, overexcitation follows.
Physical dependence can develop within a few weeks of consistent use at therapeutic doses. Misuse, meaning taking higher doses or combining gabapentin with other substances to intensify its effects, accelerates the process considerably. The absence of a federal controlled substance schedule in most countries for many years led clinicians to underestimate its dependence potential, and that misperception shaped a generation of prescribing habits that are now being reconsidered. StatPearls: Gabapentin
If you have been taking gabapentin at high doses, for a prolonged period, or alongside opioids, and you are concerned about stopping, that concern is clinically appropriate. A supervised taper is the standard of care. See also our page on opioid addiction treatment for context on gabapentin's role in opioid-using presentations.
Gabapentin is increasingly used to intensify opioid highs, which raises addiction severity.
The misuse of gabapentin in populations with opioid use disorder has been well documented since the mid-2010s. Gabapentin intensifies the euphoric effects of opioids by increasing their bioavailability and modulating shared receptor pathways, which makes it attractive to people who want to intensify the euphoric effect of opioids. Some individuals use gabapentin to manage opioid withdrawal symptoms between doses, which introduces a second substance that then requires its own taper when treatment begins.
This pattern of use creates a layered clinical picture. A client presenting with combined gabapentin and opioid dependence does not have one addiction that is easier to treat than the other. Each substance has its own withdrawal profile, its own timeline, and its own medication requirements during detox. The clinical team must sequence the detox carefully, because addressing both simultaneously without a clear protocol increases the risk of withdrawal complications.
Gabapentin is also increasingly observed in presentations alongside benzodiazepine dependence, where it is sometimes used as a substitute when benzodiazepines are not available or as an adjunct to intensify the sedative effect. Both substance classes suppress CNS activity, and combined withdrawal is medically complex. Review of gabapentin misuse: PMC8277188
FDA Warning 2019
The FDA issued a formal warning in 2019 noting that gabapentinoids substantially increase the risk of respiratory depression when combined with opioids, benzodiazepines, or other CNS depressants. This combination accounts for a meaningful share of overdose deaths in populations where gabapentin misuse is prevalent.
Source: NIDA: Opioid Overdose Crisis
Combining gabapentin with opioids substantially increases the risk of fatal respiratory depression.
The FDA issued a formal warning in 2019 noting that gabapentin and its analogue pregabalin substantially increase the risk of respiratory depression when taken with opioids, benzodiazepines, or other CNS depressants. The mechanism is additive: gabapentin slows respiration independently, and when combined with any opioid, the combined effect on the brainstem's respiratory control centres is greater than either substance alone. This combination accounts for a meaningful share of overdose deaths in populations where gabapentin misuse is prevalent.
Street fentanyl in particular creates a dangerous context. Fentanyl's extreme potency means the respiratory depression threshold is reached at very low doses. Adding gabapentin to an already-narrow safety margin removes the buffer that might otherwise allow someone to wake up or be revived. This is not a theoretical risk. It is the mechanism that has driven regulatory action across multiple jurisdictions.
For clients entering treatment with combined gabapentin and opioid dependence, medical detox is not optional. Both substances require concurrent clinical management, and the detox protocol must account for the interaction between tapering one substance while managing withdrawal from the other. Read more about gabapentin and opioids combined, including the respiratory depression risk and the FDA's formal warning about this pairing. NIDA: Opioid overdose crisis
Gabapentin withdrawal can produce seizures and requires close clinical monitoring throughout.
Gabapentin withdrawal is under-recognised in the medical literature relative to alcohol and benzodiazepine withdrawal, but it shares some of the same risks. Seizures have been documented in people stopping gabapentin abruptly, particularly those who had been using high doses, and the risk is elevated when gabapentin has been used alongside alcohol or benzodiazepines, both of which lower the seizure threshold independently. Other withdrawal symptoms include severe anxiety, sweating, tremor, nausea, insomnia, raised heart rate, and in some cases confusion and agitation.
The timeline is not uniform. Short-acting gabapentin typically produces withdrawal symptoms within 12-24 hours of the last dose, with peak intensity at days 2-4 and gradual resolution over 1-2 weeks. Extended or high-dose use can produce a more protracted course. Post-acute withdrawal symptoms, including ongoing anxiety, sleep disruption, and cognitive fog, can continue for several weeks after acute withdrawal resolves, which is why Jintara's medical team continues monitoring well beyond the first week.
The appropriate response to gabapentin withdrawal is a supervised taper, adjusting the dose reduction schedule based on how the person is responding clinically rather than following a fixed timeline. MedlinePlus: Gabapentin Understanding what to expect is one of the first things we discuss. Read more about your first week at Jintara.
Every admission at Jintara begins with a psychiatrist-led assessment before the taper starts.
The first thing that happens when a client arrives at Jintara is a thorough assessment led by our consulting psychiatrist. For a gabapentin admission, this meeting covers the client's full substance history, current gabapentin dose and duration of use, any co-administered substances, prior withdrawal experiences, co-occurring mental health conditions, and physical health status. That information determines the starting point for the taper and the level of nursing observation required during the acute phase.
The psychiatric assessment is not a brief intake questionnaire. It is a clinically meaningful meeting that can last 45 minutes to over an hour, and it may be followed by 5-7 further psychiatric consultations if medication adjustments are needed as detox progresses. This level of clinical involvement is included in Jintara's program cost. At many competing facilities, the psychiatric assessment is billed separately at approximately $300 per session, which creates a financial disincentive to use it as often as the clinical picture requires.
The nursing team, led by Lertkhwan Sukpia, Head Nurse and Medical Director, is briefed on the detox protocol immediately following the psychiatric assessment. From that point, all monitoring, medication administration, and observation follow the protocol established in that first meeting, adjusted in real time as the client's condition evolves.
“There's significant risk of detoxing at home or in a hotel unless under the care of a psychiatrist and nurses 24 hours a day, which is what we provide. The psychiatrist-led medical detox, the awake nursing care, and then on day two the medical check. That is the standard. Not many rehabs provide the full gamut of what's required for a proper, medically supervised detox.
Awake, around-the-clock nursing is what makes safe gabapentin withdrawal monitoring possible.
Jintara operates a model of 24/7 awake nursing. This means that during the acute phase of gabapentin detox, a registered nurse is present on-site throughout the night, not on-call in a separate building or sleeping between phone calls. Clients in early detox are visited every one to two hours. Vital signs, neurological observations, and a brief mental state assessment are documented at each visit. That documentation is reviewed by the clinical team each morning.
The monitoring protocol uses objective measures where they exist. For opioid withdrawal concurrent with gabapentin, the Clinical Opiate Withdrawal Scale (COWS) provides a standardised severity score that guides medication adjustment. For gabapentin withdrawal specifically, clinical observation of withdrawal severity is used alongside vital signs to determine the taper pace. The absence of a validated withdrawal scale for gabapentin equivalent to the CIWA-Ar for alcohol makes clinical observation more important, not less.
The escalation pathway is clear. If a client's vital signs trend toward a dangerous threshold or if a seizure occurs, the nursing team follows a direct transfer protocol to Bangkok Hospital Chiang Mai or RAM Hospital, both of which are Jintara's established medical partners. That pathway is rehearsed, not improvised. Learn more about how admissions works.
Most people presenting with gabapentin dependence carry a co-occurring condition that drove initial use.
Gabapentin is prescribed for nerve pain, epilepsy, and anxiety. For many people who develop dependence, the drug was initially a legitimate treatment for a condition that was not adequately controlled by other means. What changed over time was the dose, the duration, the pattern of use, or the addition of other substances. The underlying condition, whether chronic pain, anxiety, or an opioid use disorder, did not go away when dependence took hold. It became more complicated.
That clinical reality means gabapentin treatment at Jintara is not a standalone detox followed by discharge. The treatment team works concurrently on the gabapentin taper and the co-occurring condition, whether that is a mood disorder, a pain condition, or another substance use disorder. Denise O'Leary, Jintara's Clinical Director, notes that pretty much everybody, without exception, comes in with some form of anxiety or depression. In gabapentin presentations, this is almost always the case. NIMH: Substance use and mental health
Where opioid dependence is the primary driver of gabapentin misuse, the therapy program is structured accordingly. The dual diagnosis framework at Jintara does not treat the substances separately and then address the mental health condition as an afterthought. It treats the whole picture from admission onwards. Read more about dual diagnosis treatment.
Therapy at Jintara begins as soon as the client is medically stable enough to participate.
Detox is not treatment. It is the medical precondition for treatment to begin. Darren Lockie has been direct about this distinction for many years: "A detox alone does not deal with the why. Most people who do detox end up relapsing pretty quickly because they haven't dealt with the reasons they're self-medicating." For gabapentin dependence, the reasons are almost always traceable to something in the clinical history, whether it is chronic pain, anxiety, or exposure to opioids.
Once the acute withdrawal phase is controlled and the client is physically stable enough to engage, therapy begins. Cognitive Behavioural Therapy (CBT) is the primary evidence-based modality, working on the thought patterns and behavioural cycles that maintained use. Dialectical Behaviour Therapy (DBT) elements, particularly distress tolerance and emotion regulation, are integrated into group and individual sessions. For clients whose gabapentin use was entangled with trauma history, EMDR therapy is available following stabilisation.
SMART Recovery groups replace 12-step meetings at Jintara. Darren is clear about the reason: "We're a non-12-step rehab. 90-95% of people are not looking for a 12-step rehab." SMART Recovery provides a structured, evidence-based framework for building the motivational tools and coping skills that support long-term abstinence. All of this is part of Jintara's treatment program.
“Pretty much everybody, without exception, comes in with some form of anxiety or depression. With gabapentin, there's almost always something underneath the use that we need to address.
The 30-day program gives gabapentin clients time for physical stabilisation and early therapeutic work.
Jintara's standard program is 30 days at USD $12,500. For gabapentin dependence, particularly in polysubstance presentations where the taper needs to be carefully sequenced with opioid or benzodiazepine detox, this is often the minimum appropriate duration. The first week is primarily medical, focused on the taper, observation, and stabilisation. From week two onwards, the clinical balance shifts toward therapy as the medical picture becomes more manageable.
Many clients extend beyond 30 days once the acute phase resolves and they begin to experience the benefit of the therapeutic work. The risk of early discharge from a gabapentin program is the same as it is for any substance: clients who leave before the therapeutic work is embedded return to the same conditions that drove their use in the first place. The taper is a starting point, not a destination.
The 30-day program includes the psychiatric assessment, all nursing care, the Day 2 hospital diagnostic workup at Bangkok Hospital Chiang Mai (full blood panel, liver and kidney function, EKG, chest X-ray), all therapy sessions, all holistic program components (fitness, meditation, yoga, Thai massage, Reiki), and all excursions. There are no additional charges for any of these inclusions. The only optional additional cost is prescription medication dispensed by the psychiatrist, priced at Thai pharmacy rates. See program costs and inclusions.
The weeks after reaching zero are the highest-risk period for gabapentin relapse and require active support.
Reaching a gabapentin dose of zero is a clinical milestone, not the end of the withdrawal process. Denise O'Leary describes it plainly: "You're not done withdrawing until about three weeks after you get to zero." Post-acute withdrawal symptoms (PAWS), including anxiety, sleep disruption, irritability, and cognitive fog, can persist for weeks after the taper is complete. These symptoms are normal, predictable, and manageable, but they are also the primary window in which relapse risk is highest if the person is not in a supported environment.
At Jintara, clients who have completed the medical phase of treatment and entered the therapy-primary phase of their program receive ongoing nursing observation as a background safeguard. The clinical team monitors for signs of PAWS and adjusts the therapy schedule to allow for the cognitive limitations that can accompany early post-acute withdrawal. Group sessions during this phase emphasise relapse prevention planning, trigger identification, and the practical skills needed for the transition back to ordinary life.
The aftercare structure is planned before discharge, not assembled in the final days. For gabapentin clients with concurrent opioid or anxiety presentations, that plan includes referrals to outpatient support in the home country, guidance on communicating with a GP about the completed taper, and clear direction on what a relapse warning sign looks like versus what normal PAWS symptoms feel like. EMDR therapy continues to be part of the plan for clients with trauma histories, since unprocessed trauma is the most common driver of relapse across all substance use disorders.
Talk with Our Admissions Team
Common Questions About Gabapentin Addiction Treatment in Thailand
Yes. Gabapentin creates genuine physical dependence, meaning the body adapts to its presence and produces withdrawal symptoms when the dose is reduced or stopped. This can occur at prescribed therapeutic doses after several weeks of consistent use. The fact that it was legally prescribed does not change the physiological process. Dependence is not a failure of willpower. It is a predictable response to how the drug affects the nervous system.
Stopping gabapentin abruptly carries a real risk of seizures, severe rebound anxiety, and other withdrawal complications. A supervised clinical taper, reducing the dose gradually over days to weeks depending on the dose and duration of use, is the medically appropriate approach. Do not attempt to stop high-dose gabapentin without medical supervision. The speed and safety of the taper depends on your individual clinical picture.
Common gabapentin withdrawal symptoms include intense anxiety, sweating, tremor, nausea, insomnia, raised heart rate, and muscle aches. At higher doses, confusion and agitation can occur. Symptoms typically begin within 12-24 hours of the last dose and peak at days 2-4. For clients who have used gabapentin alongside opioids or benzodiazepines, the withdrawal picture is more complex, with symptoms from each substance overlapping.
Seizures have been documented during gabapentin withdrawal, particularly in people stopping abruptly after high-dose or prolonged use, and in those who have also used alcohol or benzodiazepines, which lower the seizure threshold independently. The study base for gabapentin-specific seizure risk is not as large as it is for alcohol or benzodiazepine withdrawal, but the risk is clinically documented and taken seriously in medically supervised detox settings. Abrupt cessation without supervision is not recommended for this reason.
Gabapentin intensifies the euphoric effects of opioids by increasing their bioavailability and modulating shared neurological pathways. Some people use it to intensify an opioid high. Others use it to manage opioid withdrawal symptoms between doses, which introduces a second substance that then requires clinical management when treatment begins. The combination also substantially increases overdose risk due to additive respiratory depression.
Jintara's medical detox model can manage gabapentin as either a primary substance or as part of a polysubstance presentation. The majority of gabapentin cases seen at Jintara involve concurrent opioid or benzodiazepine use, but the clinical team is equipped to manage gabapentin-primary dependence. The taper protocol and monitoring approach are the same regardless of whether gabapentin is the sole substance.
The acute medical detox phase for gabapentin typically lasts 7-14 days, depending on dose, duration of use, and whether other substances are involved. This is the period of the active taper and close clinical monitoring. Post-acute withdrawal symptoms can persist for several weeks beyond that. The 30-day program allows enough time for the acute phase to resolve and for the transition to therapy-primary treatment to begin.
That depends on your clinical picture, which the consulting psychiatrist determines at admission. Some clients require medication to manage specific withdrawal symptoms, such as heightened anxiety or sleep disruption. Prescription medications are dispensed by the psychiatrist and monitored by the nursing team throughout. The assessment at arrival, and any follow-up assessments as the detox progresses, determines what is appropriate for your situation specifically.
Pregabalin and gabapentin are related anticonvulsants with similar mechanisms and similar dependence profiles. The general principles of supervised taper and close monitoring apply to both. Specific protocol details for your presentation will be confirmed at admission assessment.
Jintara accepts a maximum of 10 clients at any time. With 32 staff members, the staff-to-client ratio is 3.2:1. This is the structural reason for the level of clinical attention described on this page. A client in the acute phase of gabapentin withdrawal is not competing for nursing time with 30 other people in various stages of treatment. The ratio means close observation is a practical reality, not a marketing claim.
Jintara operates a no-compromise escalation model. Any concern raised by the nursing team, or by the client, is acted on. The transfer pathway to Bangkok Hospital Chiang Mai or RAM Hospital is established and rehearsed. Hospital visits, including those at 2am, have occurred when the clinical picture required it. The decision to escalate is made by the nursing team, not delayed pending approval.
Contact Jintara's admissions team to describe your situation and begin the clinical pre-assessment. You do not need a formal referral. The team will ask about your substance history, current dose, and any co-occurring conditions to determine whether Jintara is the right clinical setting for your needs. If it is not, they will tell you and, where possible, suggest an appropriate alternative.